Second generation integrase transcriptase inhibitors (INSTIs) currently represent the most highly recommended option for first-line ART • HIV-infected individuals with advanced disease (e.g. CD4 count <200 cells/mm3 or AIDS), are typically underrepresented or excluded from randomized controlled trials (RCTs) • As a consequence, superiority of INSTIs-based regimens to boosted-PI regimens in the specific target population of people with advanced HIV disease, has not been demonstrated • A single RCT is now ongoing comparing B/F/TAF to DRV/c/F/TAF in people with advanced HIV disease but first results are expected in late 2021 (the LAPTOP trial https://clinicaltrials.gov/ct2/show/NCT03696160) • Novel statistical methods exist that allow the use of observational data to emulate RCTs when randomized comparisons are missing
Emulation of an RCT of Dolutegravir vs boosted-darunavir in advanced art naïve
G. Nunnari;G. F. Pellicanò.
2020-01-01
Abstract
Second generation integrase transcriptase inhibitors (INSTIs) currently represent the most highly recommended option for first-line ART • HIV-infected individuals with advanced disease (e.g. CD4 count <200 cells/mm3 or AIDS), are typically underrepresented or excluded from randomized controlled trials (RCTs) • As a consequence, superiority of INSTIs-based regimens to boosted-PI regimens in the specific target population of people with advanced HIV disease, has not been demonstrated • A single RCT is now ongoing comparing B/F/TAF to DRV/c/F/TAF in people with advanced HIV disease but first results are expected in late 2021 (the LAPTOP trial https://clinicaltrials.gov/ct2/show/NCT03696160) • Novel statistical methods exist that allow the use of observational data to emulate RCTs when randomized comparisons are missingPubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
